EXHIBIT 99.1


                            [LECTEC CORPORATION LOGO]

Contact
- -------
William Johnson, Controller
Phone: (952) 933-2291 ext. 24
Email:  bjohnson@lectec.com


                   LECTEC CORPORATION ANNOUNCES CHANGES TO ITS
                        MANAGEMENT AND BOARD OF DIRECTORS

NOVEMBER 28, 2006 - - EDINA, MN - - LECTEC CORPORATION (OTCBB: LECT) LecTec
Corporation announced today that Alan C. Hymes, M.D. has resigned from his
positions as Chief Executive Officer, Chief Financial Officer, Chairman and
Director of LecTec, effective November 21, 2006, in order to spend time with his
family and to pursue other scientific interests. The Board of Directors of
LecTec also announced that it has elected Judd A. Berlin to the offices of Chief
Executive Officer, Chief Financial Officer, and Chairman at LecTec.

"Dr. Hymes co-founded LecTec in 1977 and helped develop many of its patents,"
stated Judd Berlin, the newly appointed Chief Executive Officer, Chief Financial
Officer, and Chairman of LecTec. "We are immensely grateful for his nearly 30
years of service to LecTec and respect his desire to now pursue other scientific
interests and spend more time with his family."

Mr. Berlin has been a director of LecTec since May 29, 2003. Mr. Berlin is a
multinational entrepreneur and founder of Hello Corporation, an Asian-based
company operating call centers for Fortune 100 companies. Mr. Berlin has also
founded companies in Europe, the Middle East, and Asia in food distribution,
broadcasting, and entertainment production. Mr. Berlin has an MBA from St.
Thomas University in St. Paul, Minnesota.

LecTec also announced today that it has elected a new director, Daniel C. Sigg
MD PhD, to LecTec's Board of Directors. Dr. Sigg, a Swiss national, is currently
serving as Sr. Manager in the R&D Division of Cardiac Rhythm Disease Management
at Medtronic, Inc., a leading medical device and technology company, which he
joined in 2001. Dr. Sigg is a board-certified anesthesiologist and has
significant clinical experience. His pre-clinical expertise includes both
academic and industrial R&D. His areas of interest and expertise include
cardiovascular physiology, biotechnology, pharmacology, and local drug delivery.
To date, Dr. Sigg has published 17 peer-reviewed papers, as well as numerous
book chapters and abstracts, and is inventor of two issued and 14 pending U.S.
patents. Dr. Sigg obtained his Medical Degree from the University of Basel,
Switzerland, and his PhD degree in Physiology from the University of Minnesota.
Dr. Sigg speaks German, English, French, and some Italian.

"Dr. Sigg brings significant experience in medicine, medical research, and
intellectual property to LecTec. As a Swiss native, he has the acumen to assist
the Board in furthering LecTec's patent portfolio interests in the European
Union and Switzerland," stated Judd Berlin. "For example, our licensing partner
Novartis is a world-leading pharmaceutical company headquartered in
Switzerland."

ABOUT LECTEC CORPORATION

LecTec Corporation is primarily an intellectual property licensing and holding
company. The Company's primary focus is to obtain royalty income through
licensing agreements related to patents that the Company owns based on its
advanced skin interface technologies. The Company was an innovator in
hydrogel-based topical delivery of therapeutic over-the-counter medications,
which provide alternatives to topical creams and ointments. A hydrogel is a
gel-like material having an affinity for water and similar compounds. These gels
are ideal for delivering medication onto the skin. The Company holds multiple
domestic and international patents on its hydrogel technology.



This press release contains forward-looking statements that may include
statements regarding intent, belief, or current expectations of the company and
its management. These forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that may cause the
Company's actual results to differ materially from the results discussed in
these statements. Factors that might cause such differences are detailed from
time to time in the Company's filings with the Securities and Exchange
Commission, and particularly in Exhibit 99.01 to our Form 10-KSB for the year
ended December 31, 2005.